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A computer model of gluconeogenesis and lipid metabolism
in the perfused liver
Elie Chalhoub, Richard W. Hanson, and Joanne M. Belovich

Chalhoub E, Hanson RW, Belovich JM. A computer model of
gluconeogenesis and lipid metabolism in the perfused liver. Am J
Physiol Endocrinol Metab 293: E1676–E1686, 2007. First published
October 2, 2007; doi:10.1152/ajpendo.00161.2007.—A mathematical
model of the perfused rat liver was developed to predict intermediate
metabolite concentrations and fluxes in response to changes in various
substrate concentrations in the perfusion medium. The model simulates gluconeogenesis in the liver perfused separately with lactate and
pyruvate and the combination of these substrates with fatty acids
(oleate). The model consists of key reactions representing gluconeogenesis, glycolysis, fatty acid metabolism, tricarboxylic acid cycle,
oxidative phosphorylation, and ketogenesis. Michaelis-Menten-type
kinetic expressions, with control by ATP/ADP, are used for many of
the reactions. For key regulated reactions (fructose-1,6-bisphosphatase, phosphofructokinase, pyruvate carboxylase, pyruvate dehydrogenase complex, and pyruvate kinase), rate expressions were
developed that incorporate allosteric effectors, specific substrate relationships (e.g., cooperative binding), and/or phosphorylation/dephosphorylation using in vitro enzyme activity data and knowledge of the
specific mechanisms. The model was independently validated by
comparing model predictions with 10 sets of experimental data from
7 different published works, with no parameter adjustments. The
simulations predict the same trends, in terms of stimulation of substrate uptake by fatty acid addition, as observed experimentally. In
general, the major metabolic indicators calculated by the model are in
good agreement with experimental results. For example, the simulated
glucose/pyruvate mass yield is 43% compared with the average of
45% reported in the literature. The model accurately predicts the
specific time constants of the glucose response (2.5– 4 min) and the
dynamic behavior of substrate and product fluxes. It is expected that
this model will be a useful tool for analyzing the complex relationships between carbohydrate and fat metabolism.
liver; metabolism; mathematical model; gluconeogenesis; lipids
GLUCONEOGENESIS IN THE LIVER has been studied extensively over
the past four decades, resulting in a better understanding of the
factors that regulate the rates of glucose synthesis from various
substrates and the effects of substances such as fatty acids and
ethanol on this process. Despite this wealth of experimental data,
the challenge remains to be able to predict how alterations in
specific physiological stimuli will affect the distribution of fluxes
in the liver and, in particular, the rate of hepatic gluconeogenesis.
Metabolic models of the liver can be divided into two broad
categories: lumped models that consider the organ as wellmixed and distributed-in-space models that consider the heterogeneous nature of the organ. Garfinkel and colleagues (1, 3)
developed the first well-recognized model of liver metabolism

using detailed in vitro-based kinetic expressions. Their model
of gluconeogenesis consisted of kinetic expressions for reactions taking place between phosphoenolpyruvate (PEP) and
glucose, with the net flux through enolase (interpreted from
experimental data under a variety of substrates) taken as
the input to the model. Because the reactions kinetics of
pyruvate carboxylase (PC) and liver-type pyruvate kinase
(PK-L) were not considered, the futile cycling that occurs
through these reactions was neglected. Moreover, the model
lacked ATP and redox balances, the ketogenic reactions, and
some of the dehydrogenase reactions that are critical to controlling the relationships between lipid metabolism and
gluconeogenesis. Furthermore, this work was done before
knowledge about important regulator effects, such as cAMPmediated phosphorylation of key regulatory enzymes like
PK-L and fructose-1,6-bisphosphatase (FBPase) and the allosteric effects of fructose-2,6-bisphosphate (F-2,6-P2). Using
a similar approach, Bergman and El Refai (6) simulated
glycogen synthesis and degradation and glucose output at fixed
rates of gluconeogenesis. A subset of glycolytic and glycogenolytic reactions around glucose 1-phosphate, glucose 6-phosphate (G-6-P), and fructose 6-phosphate (F-6-P) was the subject of a power law formalism model applied to an in vitro
experimental system using tissue extracts (59). Hepatic tricarboxylic acid (TCA) cycle flux was modeled as an isolated
subsystem, using parameter values that were time-dependent
and adjusted for each substrate (24, 25).
More recent modeling approaches have eschewed dynamic
models for ones based on steady state, without the need for
reaction kinetics. These include the steady-state flux balance
analysis (FBA) approach with optimization of a presumed
objective function (including energy constraints; see Refs. 11
and 41), FBA with Fischer discriminant analysis (13), and the
FBA and thermodynamic constraint-based model (5). All of
these approaches consist of a comprehensive system of reactions describing hepatic metabolism, and they provide insight
into the distribution of fluxes at various steady states. The
approach by Beard and Qian (5) is particularly interesting since
it uses both FBA and thermodynamic constraints; even without
kinetic parameters, it can predict metabolite concentrations at
steady state and analyze the control structure. However, these
FBA-based methods require the use of experimental measurements of fluxes as inputs to the model and, since they lack
reaction kinetics, have limited predictive value.
The liver, in reality, has a very heterogeneous organization,
and several published works have considered its distributed-

in-space nature by representing the liver as a system of parallel
tubular reactors (49, 55) for prediction of the elimination rates
of specific drugs. More recently, a distributed-in-space model,
which employs a simplified reaction system representing gluconeogenesis and associated pathways and takes into account
heterogeneity in enzyme distribution, i.e., “zonation” (32), has
been used to investigate the role of zonation in the relative rates
of glycolysis and gluconeogenesis along the sinusoid in the
fasted, the resting state, and to study the effect of high-intensity
exercise on glucose production (12). Although this distributed
model uses available information concerning liver structure
and enzyme distributions, there are few data available to
validate the model’s predictions at this level of detail. Most of
the available data are derived from the entire organ, such as
measurements of the concentrations of intermediates from
tissue homogenates, metabolic flux determinations from arterial-venous differences (for in vivo), or input-perfusate concentrations (for perfused liver), with or without tracers. This
makes it nearly impossible to thoroughly validate a distributed
model. Furthermore, most measurements of enzymatic kinetic
parameters in liver also represent the average value for the
tissue.
In this work, we have developed a lumped model of hepatic
metabolism, with an emphasis on gluconeogenesis and fatty
acid metabolism. Although the model was kept as simple as
possible to achieve tractability, reactions are included as necessary to account for the relationship between gluconeogenesis
and lipid metabolism. Additional reactions, such as those
occurring mainly in glycolysis, are included to increase the
flexibility of the model for future applications. MichaelisMenten-type kinetic expressions were used for many of the

reactions. However, the exclusive use of these expressions was
inadequate for achieving the expected physiological results.
For key regulated reactions [FBPase, phosphofructokinase
(PFK), PC, pyruvate dehydrogenase complex (PDC), and PK],
rate expressions were used that incorporate allosteric effectors,
specific substrate relationships (e.g., cooperative binding),
and/or phosphorylation/dephosphorylation and were developed
using in vitro enzyme activity data and knowledge of the
specific mechanisms.
The model is first used to represent the 24-h-fasted rat liver
in vivo. Because many of the most well-controlled, data-rich
experiments available in the literature have been performed
with the perfused liver, we then modified the model to account
for the conditions of the ex vivo liver in a recirculated perfusion system. With the same set of kinetic parameters, this
model is used to predict the effect of fatty acid uptake on
gluconeogenesis rates during separate lactate and pyruvate
perfusions. Our simulations are then compared with experimental data available from the literature.
METHODOLOGY

Metabolic pathway. The metabolic pathways considered in the
model development are glycolysis, gluconeogenesis, the TCA cycle,
fatty acid oxidation, fatty acid synthesis, ketogenesis, oxidative phosphorylation, and glycogen degradation (Fig. 1). Each pathway is
represented by a few key reactions, mainly those essential for defining
the relationships between lipid metabolism and gluconeogenesis.
The rate expressions are given in Supplemental Table S1 (Supplemental data for this article are available online at the American
Journal of Physiology-Endocrinology and Metabolism website). The
rate mechanism for transport between the blood and tissue domains is

Fig. 1. Reaction network considered in tissue
model. Broken lines indicate a series of reactions that have been lumped together. Detailed stoichiometry for each reaction shown
here is given in Supplemental Table S1. The
ATPase reaction represents the total of all
ATP-utilizing reactions that are not considered explicitly in the model. GK, glucokinase; G-6-Pase, glucose-6-phosphatase;
Glyphos, glycogen phosphorylase; OxPhos,
oxidative phosphorylation; PK, pyruvate
kinase; PC, pyruvate carboxylase; PDC,
pyruvate dehydrogenase complex; LDH,
lactate dehydrogenase; BHBdh, ␤-hydroxybutyrate dehydrogenase; GAP, glyceraldehyde 3-phosphate; GR-3-P, glycerol
3-phosphate; PEP, phosphoenolpyruvate;
AcAc, acetoacetate; BHB, ␤-hydroxybutyrate; AcCoA, acetyl-CoA; ALA, alanine.

described by facilitated diffusion. The kinetic expressions for some
of the relatively irreversible reactions are expressed by simple
Michaelis-Menten kinetics, with modulation by ADP/ATP and
NADH/NAD⫹ (RS), as relevant. Reversible, near-equilibrium reactions are represented by a simplified form of a reversible, ping-pong
mechanism, with the Haldane equation used to relate kinetic parameter values at near-equilibrium and to ensure consistency with thermodynamic constraints.
The kinetic parameters were generally obtained either from in vitro
kinetic studies with purified enzymes, by calculation from in vivo data
and the assumed rate expression, or a combination of these methods.
For reversible reactions, the equilibrium constants and maximal
velocities (Vmax) were obtained from the literature; the forward
Michaelis constant (Km) was set equal to the product of the substrate
concentrations, and the reverse Km was calculated based on the in vivo
flux and concentrations. Michaelis-Menten kinetics were often used as
simplifications for a series of reactions and do not necessarily represent a specific enzyme. Most often, parameters were calculated from
in vivo data rather than from in vitro kinetic studies of purified
enzymes. The Km was set equal to the approximate steady-state
concentration of the corresponding substrate, whereas the Vmax was
calculated by setting the reaction expression equal to the corresponding in vivo flux expected during the 24-h-fasted state (given in
Table 1). The specific approach used for each reaction is indicated in
Supplemental Table S1.
In some cases, Michaelis-Menten and reversible kinetics, as described above, were found to be inadequate for achieving the expected
physiological responses during gluconeogenesis and lipid metabolism. Thus the rate expressions were modified to take into account
allosteric effectors, specific substrate relationships (e.g., cooperative
binding), and phosphorylation/dephosphorylation. Detailed kinetic
expressions were developed for five regulated reactions (FBPase,
PFK, PC, PDC, and PK) using in vitro enzyme activity data and
knowledge of the specific mechanisms gleaned from the literature
(Supplemental Table S1). The rate expression of FBPase includes the
effect of phosphorylation and dephosphorylation by means of cAMPdependent protein kinase, along with AMP as an uncompetitive
inhibitor and F-2,6-P2 as a competitive inhibitor. The PFK expression
is based on the bi-bi mechanism, where ATP acts as substrate inhibitor
while AMP and F-2,6-P2 are activators. The kinetics of the lumped
reaction RPYR3 PEP, where PYR is pyruvate, is represented by the
kinetics of the PC reaction, with activation by acetyl-CoA (AcCoA)
and inhibition by ADP, where ADP plays the role of uncompetitive
inhibition with respect to pyruvate and competitive inhibition with
respect to ATP. The PK expression reflects phosphorylation as an
allosteric effect mediated by cAMP-dependent protein kinase, inhibition by both ATP and alanine, and activation by fructose-1,6-bisphosphate (F-1,6-P2). One of the PK model parameters (K F-1,6-P2,PK) was
modified significantly from the original kinetic model (F. Pusca and J.
Belovich, unpublished observation) to provide the expected fluxes at
physiological concentrations of allosteric regulators not considered in
the previous in vitro studies. The rate kinetics of PDC were developed
to account for inhibition by AcCoA, the ATP-to-ADP ratio, and the
NADH-to-NAD⫹ ratio and the effect of inhibition by phosphorylation
of the enzyme by pyruvate dehydrogenase kinase that is mediated
through ATP. Kinetic parameters were obtained by fitting the reaction
expressions to in vitro kinetic data using least-squares regression.
Although cytosolic-mitochondrial compartmentation is not considered specifically, the mitochondrial redox state is significantly different from the cytoplasmic redox state, and this difference between the
two compartmental concentrations was found to significantly affect
reaction rates involving NADH-coupled enzymes. A pseudomitochondrial compartment was established only for NADH/NAD⫹, with
the assumption that the mitochondrial redox ratio, RSm [defined as
CNADH(m)/C NAD⫹(m), where CNADH(m) and CNAD⫹(m) are the mitochondrial concentrations of NADH and NAD⫹, respectively], is in equilibrium with the cytosolic ratio RS [CNADH(c)/CNAD⫹(c), where

Table 1. Steady-state results

Metabolite concentrations,
mol/gww hep
Glc,tissue
Glc,blood
F-6-P
F-1,6-P2
G-6-P
Glycogen
GAP
GR-3-P
PEP
PYR
Blood
Tissue
LAC
Blood
Tissue
AcAc
Blood
Tissue
BHB
Blood
Tissue
ALA
Blood
Tissue
AcCoA
ATP
ATP ⫹ ADP ⫹ AMP
NADH(m)/NAD(m)⫹
NADH(c)/NAD(c)⫹
Fluxes, mol䡠gww
hep⫺1 䡠 min⫺1
JGLC,b⫺t,net
JLAC,b⫺t,net
JBHB,b⫺t,net
JALA,b⫺t,net
JPYR,b⫺t,net
JFFA,b⫺t,net
JGLR,b⫺t,net
GK
G-6-Pase
GI
GAP3F-1,6-P2
FBPase
PFK
PEP3GAP
PK
PYR3PEP
LDH
GLR3GR-3-P
GR-3-P3GAP
FAT_syn
FFA3AcCoA
TG_f
AcCoa3AcAc
OxPhos
TCA
JTG,b⫺t,net
PDC

Calculated

Experimental

6.3
5.55
0.039
0.0023
0.087
109
0.015
0.25
0.0061

4.5–6
5.07–5.48
0.046
0.016
0.102
109–175
0.021
0.31
0.05

0.024
0.023

0.062
0.059

15
7, 34, 57

0.59
0.46

0.85–1.2
0.35–0.95

15
7, 34, 66

1.47
1.61

0.68–0.99
0.5–0.78

15, 29
7, 34, 66

2.07
5.6

0.85–1.7
2.23

15, 29
7, 34, 66

0.23
0.18
0.13
3.46
5.07
0.25
0.0021

0.56
0.475
0.13
3.43
3.68–5.2
0.18
0.0017

15
7
7
7, 27
7, 27
66
57, 66

1.11
⫺1.38
1.09
⫺0.59
⫺0.12
⫺0.87
⫺0.96
0.57
1.68
1.07
2.15
1.08
0.007
2.08
0.0003
2.09
1.26
0.099
0.06
0.71
0.86
0.11
4.83
8.20
1.37
0.03
0.0023

1.2–1.9
⫺1.54
0.93
⫺0.64
⫺0.14
⫺0.8
⫺0.14

30, 40, 53
15
15
15
15
15
15

5.56
3–3.6, 7.9

30
45, 30

1.75

Ref. No.

7
15
7
7
7
7
57, 66
7
7

30

Steady-state results, at the overnight fasted state, experimental and calculated using Eqs. 1 and 2, with upstream blood concentrations as follows:
*
*
*
*
CClc
⫽ 0.12 mM (7); CFFA
⫽ 1.5
⫽ 4.6 mM (7); CLAC
⫽ 1.7 mM (7); CPYR
*
*
mM (7, 8); CAcAc
⫽ 0.43 mM (7, 8); CBHB
⫽ 1.2 mM (8). Physical parameters
used in Eqs. 1–2 are as follows: Fblood ⫽ 6.57 ml/min; Vtissue ⫽ 5.25 cm3 (12);
Vblood ⫽ 1.03 cm3 (12). Reaction rates (Ri) and transport rates (Ji,b⫺t) are given
in Supplemental Table S1 (⫹, production rate; ⫺, uptake rate). See text for
definitions.

CNADH(c) and CNAD⫹(c) are the cytosolic concentrations of NADH and
NAD⫹, respectively]; this assumption is expressed as RSm ⫽
Keq,RS ⫻ RS. The equilibrium constant Keq,RS is calculated from the
ratios of free cytosolic and mitochondrial CNADH/CNAD⫹ at the fasted
steady state, obtained from measurements of CLAC/CPYR (where LAC
indicates lactate) and CBHB/CAcAc, (where BHB indicates ␤-hydroxybutyrate and AcAc is acetoacetate), respectively, at equilibrium.
Model of the in vivo liver. The liver is represented by two wellmixed domains representing the tissue and blood compartments, with
mass balances for each metabolite i given by:
dC i,tissue
⫽ Ji,b⫺t ⫹
dt

兺R
j

(1)

i, j

冉 冊

Fblood
dC i,blood
Vtissue
⫺ Ji,b⫺t
⫽ (C*i ⫺ Ci,blood)
dt
Vblood
Vblood

(2)

where C*i is the concentration of each metabolite in the blood upstream of the liver (calculated from a weighted average of portal vein
and hepatic artery concentrations; Table 1); Ci,tissue and Ci,blood are
concentrations of metabolite i in the tissue and blood domains,
respectively; Ji,b⫺t is the transport rate between the blood and tissue
domains (mol 䡠 g tissue⫺1 䡠 min⫺1); Ri,j is the reaction rate of each
reaction j with metabolite i as substrate or product; and Fblood is the
blood flow rate through the liver. The ratio of tissue volume to blood
volume (Vtissue/Vblood) is used for conversion of units of Ji,b⫺t from
tissue volume units to blood volume units.
The mass balance equation of the tissue (Eq. 1) is written for each
intermediate within the cell shown in the metabolic pathway in Fig. 1
(i.e., glucose, lactate, alanine, acetoacetate, ␤-hydroxybutyrate, glycogen, glycerol, triglyceride, fatty acid, pyruvate, ATP, NADH,
G-6-P, F-6-P, F-1,6-P2, glyceraldehyde 3-phosphate, PEP, and
AcCoA), using the stoichiometry given in Supplemental Table S1.
The mass balance for GTP is included within the balance for ATP by
assuming a fast equilibration of neucleoside diphosphokinase. Equation 2 is written for every intermediate that occurs in the blood, as
shown in Fig. 1 (i.e., glucose, lactate, alanine, acetoacetate, ␤-hydroxybutyrate, glycerol, triglyceride, fatty acid, and pyruvate). Equations 1 and 2 were solved simultaneously at steady state. Because
enzyme kinetic parameters were in general obtained from liver extracted from fasted rats, and the upstream blood concentrations (C*i )
were obtained from blood samples from fasted rats, we assume that
this simulation represents the conditions in vivo for a liver from a
24-h-fasted rat.
Model of the perfused liver. The model was then modified to
represent the liver perfused ex vivo in a recycling perfusion system, as
used by Williamson et al. (64) and others (see Fig. 2). The tissue mass
balance is given by Eq. 1. The mass balance in the blood domain is
given by:

冉 冊

dC i,blood
Fperfusate
Vtissue
⫺ Ji,b⫺t
⫽ (Ci,perfusate ⫺ Ci,blood)
dt
Vblood
Vblood

(3)

where Ci,perfusate is the concentration of metabolite i in the perfusion
medium and Fperfusate is the perfusate flow rate. Because the content
of the blood domain is actually the saline perfusion medium rather
than blood, Eq. 3 is only written for those metabolic intermediates
expected to occur in the perfusate (i.e., glucose, lactate, alanine,
acetoacetate, ␤-hydroxybutyrate, pyruvate). The perfusion medium
vessel, which we also assumed to be well-mixed, is represented by the
following mass balance for each metabolic intermediate that exists in
the blood domain:
dC i,perfusate
Fperfusate
⫽ (Ci,blood ⫺ Ci,perfusate)
dt
Vperfusate
where Vperfuate is the volume of the perfusion medium.

(4)

Fig. 2. Schematic of perfusion system that is the basis for the mathematical
model. Ci,tissue and Ci,blood, concentrations of metabolite i in the tissue and
blood domains, respectively; Ji,b⫺t, transport rate between the blood and tissue
domains; F, flow; Vperfusate, volume of the perfusion medium; Ci,perfusate,
concentration of metabolite i in the perfusion medium.

The quantities Fperfusate and Vperfusate in Eq. 4 are assigned values
that match the specific experimental conditions from the literature that
are being simulated.
It is generally recognized that the in vivo environment of an
enzyme may be different from the in vitro experimental conditions
from which the parameters are determined. Thus parameter values
(Supplemental Table S1) were fine tuned to within ⫾ 10% of their
original values using the parameter estimation method of generalized
reduced gradient, nonlinear optimization to fit the dynamic solution of
Eqs. 1, 3, and 4 to the experimental lactate perfusion data of Williamson et al. (64) (Fig. 3). Three exceptions to this ⫾ 10% constraint
were found to be necessary to achieve the expected physiological
results: KF-1,6-P2,PK,FBPase was decreased 16%, KcAMP,FBPase was decreased 20%, and Km,PEP,GAP (where GAP is glyceraldehyde 3-phosphate) was decreased 90%. This last parameter appears in the kinetic
expression for the lumped reversible reaction RPEP7GAP. The large
change in this parameter value indicates that the method of setting the
Km equal to the substrate concentration does not yield the expected
results at physiological conditions for this reaction.
RESULTS

The model was first solved at conditions representing the
in vivo 24-h-fasted state, using the kinetic parameters in
Supplemental Table S1 and the physical parameters and upstream blood concentrations given in the legend of Table 1.
The steady-state results are shown in Table 1 compared with
experimental values available from the literature. In general,
there is excellent agreement between calculated and experimental values, with the exceptions of F-1,6-P2 and PEP, which
are significantly lower than the in vivo measurements (which
are already very low), and the flux through PK, which becomes
completely inhibited in the model at this state.
The model was then used to simulate the lactate perfusion
protocol of Williamson et al. (64) using the same set of kinetic
parameters used in the in vivo model (Supplemental Table S1,
as described above), with input functions and initial conditions
given in Table 2. The simulation results compared with their
experimental data are shown in Fig. 3. The first 30 min
represents the liver, just removed from the animal and perfused
with saline. The replacement of the blood with saline, which
contains no substrate, results in large concentration gradients
of metabolites such as glucose, ␤-hydroxybutyrate, and acetoacetate; this leads to the very brief spikes in release of these

Fig. 3. Gluconeogenic fluxes calculated from the perfusion model using lactate as substrate. Rats were fasted for 24 h before perfusion; 0 ⬍ time (t) ⱕ 30 min,
saline preperfusion (no substrate); 30 ⬍ t ⱕ 60 min, lactate perfusion; 60 ⬍ t ⱕ 90 min, lactate ⫹ fatty acid (FA) perfusion. Details are given in Table 2. Filled
squares are experimental data from perfused fasted livers from Williamson et al. (64) using a perfusion medium of Krebs-Henseleit bicarbonate buffer, with 4%
BSA, in a recirculated system; solid lines are simulations, using Eqs. 1, 3, and 4, with perfusate flow (Fperfusate) ⫽ 50 ml/min and Vperfusate ⫽ 100 ml
(corresponding to the experimental protocol). All other parameters as given in Supplemental Table S1. To view the details of the lactate and FA perfusion, the
y-axis scale was expanded, which cut off the initial peak values [in mol 䡠 gram wet weight hepatocyte (gww hep)⫺1 䡠 min⫺1] given here: glucose production:
7.4; BHB production: 2.1; AcAc production: 6.0. PYR, pyruvate; FBPase, fructose-1,6-bisphosphatase; PFK, phosphofructokinase; TCA, tricarboxylic acid.

substances from the tissue. Some of the glucose production
also results from gluconeogenesis from endogenous substrates
and a small amount from glycogenolysis. Lactate uptake drops
quickly to zero because of the absence of substrate in the
perfused saline.

The simulated transition from saline perfusion to lactate
perfusion begins at time (t) ⬎ 30 min. As expected, lactate
uptake increases quickly and overshoots before settling to a
steady-state value. This overshoot results from stimulation of
lactate transport by the large concentration gradient between

*
⫽ the sum of the uptake rate of FFA and rate of endogenous fatty acid oxidation.
RFA-endo ⫽ rate of endogenous fatty acid oxidation, normalized to mol C16 (palmitate); JFA-b⫺t

*
RFA-endo ⫽ 0.0573
J FA-b⫺t
⫽ 0.0573 ⫹
mol 䡠 gww hep⫺1 䡠 min⫺1
0.27{(1 ⫺ exp关⫺(t ⫺
CPYR,perfusate ⫽ 2{1 ⫺
60)/)兴},  ⫽ 2.5 min;
exp关⫺(t ⫺ 30)/ 兴},
experimental FA uptake
mM (constant PYR
not reported; assumed
concentration of 2 mM in
equal to data from lactate
perfusate);  ⫽ 3 min.
perfusion. CPYR,perfusate ⫽
CLAC,perfusate calculated
2 mM
from Eq. 3

RFA-endo ⫽ 0.105
mol 䡠 gww
hep⫺1 䡠 min⫺1
Ci,perfusate (t ⫽ 0) ⫽
0; i ⫽ Glc, LAC,
BHB, AcAc,
PYR (saline
preperfusion
contains no
substrate)
*
J FA-b⫺t
⫽ 0.0573 ⫹
0.27{1⫺ exp关⫺(t ⫺
60)/兴}  ⫽ 2.5 min;
total rate of 0.33
mol 䡠 gww
hep⫺1 䡠 min⫺1
determined from
experimental
measurements of
oleate infusion (65).
CLAC,perfusate ⫽ 10 mM

RFA-endo ⫽ 0.105
mol 䡠 gww
hep⫺1 䡠 min⫺1,
assumed to be
equal to
experimental
measurements
of ketone
production
during this
period (65)
Ci,perfusate (t ⫽ 0) ⫽
0; i ⫽ Glc, LAC,
BHB, AcAc
(saline
preperfusion
contains no
substrate)

RFA-endo ⫽ 0.0573
mol 䡠 gww
hep⫺1 䡠 min⫺1, as
estimated (65) from
ketone production.
CLAC,perfusate ⫽ 10{1 ⫺
exp关⫺(t ⫺ 30)/兴},
mM (constant LAC
concentration of 10 mM
in perfusate);  is time
constant for achieving
change in susbstrate
concentration, set to 4
min

Pyruvate ⫹ FA
(90 ⬍ t ⱕ 120)
Pyruvate infusion
(30 ⬍ t ⱕ 90)
Saline preperfusion
(0 ⬍ t ⱕ 30)
Initial conditions used
in Eq. 4

Lactate infusion
(30 ⬍ t ⱕ 60)

Lactate ⫹ FA
(60 ⬍ t ⱕ 90)

Initial conditions used
in Eq. 4

Saline preperfusion
(0 ⬍ t ⱕ 30)

Pyruvate Perfusion
Lactate Perfusion

Table 2. Initial conditions and input functions used in simulation of the perfused liver

the perfusate and tissue. At steady state, ⬃50% of the lactate
(by mass) is converted to glucose, according to both the
simulation and experimental data. According to the reported
experimental data, the remaining carbon goes in the TCA cycle
for oxidation. Our model underestimates TCA flux by ⬃50%
and instead overestimates total ketone body (␤-hydroxybutyrate and acetoacetate) production. Futile cycling through the
PFK-FBPase system accounts for 10% of the net gluconeogenic flux. Although the exact amount of this futile cycling
in vivo is difficult to quantify, it has been reported that, in the
fasted state, there is essentially no futile cycling (31).
Infusion with fatty acids is simulated beginning at t ⬎ 60
min (Fig. 3). The additional energy generated by hepatic fatty
acid oxidation increases the gluconeogenic flux so that both
glucose production and lactate uptake increase, with close
correspondence to the experimental data. The increased
AcCoA concentration, derived from the oxidation of exogenous fatty acids, inhibits flux through PDC and increases flux
through PC, while increasing ketogenesis, as expected. The
oxidative phosphorylation also increases, similar to reported
values.
The sensitivities of glucose production and lactate uptake
were investigated for the four parameters (Km,PEP,GAP,
KF-1,6-P2,PK, KF-1,6-P2,FBPase, and KcAMP,FBPase) that needed to be
modified significantly from the original values obtained from
in vitro or in vivo data. Figure 4 shows the dynamic flux
profiles during lactate perfusion, where each parameter is
varied individually, while all other parameters are held
constant at the values given in Supplemental Table S1. The
results are most sensitive to KF-1,6-P2,FBPase, KcAMP,FBPase, and
KF-1,6-P2,PK, but sensitivity is still relatively low at these conditions, since a doubling of the parameter leads to, at most, a
10% change in the flux of glucose and lactate.
The model, with the same set of parameters as given in
Supplemental Table S1, was then used to simulate a variety of
pyruvate, lactate, and fatty acid perfusion conditions, with the
results compared with independent experimental data sets from
the literature. Figure 5 shows the results of pyruvate perfusions. Although the model underestimates both the pyruvate
uptake and glucose production compared with experimental
values, the yields of glucose from pyruvate calculated from the
model are nearly the same as those reported by Williamson
et al. in Fig. 5A in which 48% by mass of pyruvate is converted
to glucose experimentally while the model predicts 45% conversion; in Fig. 5B, the experimental conversion is 50% while
the calculated conversion is 41%. The addition of fatty acids at
t ⫽ 90 min (Fig. 5B) increases pyruvate uptake, glucose
production, and lactate production with trends similar to the
published experimental data (64).
Figure 6 shows the calculated glucose production compared
with experimental data as reported in two separate published
works using lactate as substrate (22, 27). The simulations are
again using the same parameters given in Supplemental Table
S1. Although the model underestimates glucose production by
⬃40% in Fig. 6, A and C, the prediction is nearly identical to
the experiment in Fig. 6B.
The accuracy of the model’s dynamic response for both
lactate and pyruvate perfusions is evaluated in Fig. 7. In the
retrograde perfusion (9), the time constants for the glucose
response were 2.5– 4 min for both the addition and removal of
substrate, with similar response times calculated by the model.

Fig. 4. Simulations using the perfusion model,
using parameters as given in Supplemental
Table S1, with the variations in a single parameter, as specified. Solid lines: 2⫻ Supplemental Table S1 value; broken lines: Supplemental Table S1 value; dotted line: 0.5⫻ Supplemental
Table S1 value. A: Km,PEP,GAP; B: KFBPase; C:
KF-6-P,PFK; D: KF-1,6-P2,PK.

The response time from the antegrade perfusions (36) was
slower, with the steady state not achieved within 15 min of
lactate perfusion.
DISCUSSION

The aim of this study was to develop a model capable of
representing the complexity of gluconeogenesis and lipid metabolism and their interactions in the liver. Parameter values
were determined from a combination of in vitro enzyme
kinetics and data obtained from in vivo fasted rats. One set of
experimental perfusion data from Williamson et al. (64) were
used for fine tuning parameters (Fig. 3). This model was then
independently validated by comparison of model predictions
with data obtained from 10 different experiments from 7
different publications.
The glucose production and lactate uptake rates obtained
from our simulation are in excellent agreement with the values
reported by Williamson et al. (Fig. 3). These values are 50%
lower than those reported by Ross et al. (51, 52) and Exton and

Park (20), with this difference partially attributed to the use of
red blood cells in the perfusion medium by both of these
groups. This could lead to higher rates of oxidative phosphorylation and thus energy availability for gluconeogenesis. The
higher gluconeogenic rates have also been attributed by Exton
and Park to the possible presence of an activator such as
glucagon in the faction V albumin used in their perfusion
medium (20, 64). Furthermore, Exton and Park used a different, nonrecycling perfusion system.
Conversion to glucose accounts for 60% of lactate uptake
(Fig. 3); the remaining 40% is converted to AcCoA through
PDC. This latter rate of conversion is in good agreement with
the Williamson data, with the small difference because our
model assumes negligible pyruvate formation during perfusion
with lactate. The endogenous fatty acid oxidation and the PDC
flux constitute the source of AcCoA. Compared with the
experimental data (20, 51, 52, 65), our simulation overestimates AcCoA conversion to ketone bodies and underestimates
its oxidation via the TCA cycle. The low ratio of TCA/

Fig. 5. Gluconeogenic fluxes calculated from
perfusion model using pyruvate as the substrate. Rats were fasted for 24 h before perfusion. Symbols are experimental data from the
literature from perfused fasted livers, using a
perfusion medium of Krebs-Henseleit bicarbonate buffer with 4% BSA in a recirculated
system, with substrate added continuously to
the medium. Solid lines are simulations, using
Eqs. 1, 3, and 4, with Fperfusate ⫽ 50 ml/min,
Vperfusate ⫽ 100 ml; simulation details are
given in Table 2, and all other parameters are
given in Supplemental Table S1. A: 0 ⬍ t ⱕ 30
min: saline preperfusion (no substrate); 30 ⬍
t ⱕ 120 min: PYR perfusion. Experimental
data are as follows: ■, from Williamson et al.
(67); Œ, from Williamson et al. (63). B: 0 ⬍
t ⱕ 30 min: saline preperfusion (no substrate);
30 ⬍ t ⱕ 90 min: PYR perfusion; 90 ⬍ t ⱕ
120 min: PYR ⫹ FA perfusion. Experimental
data are as follows: }, from Williamson et al.
(64); ■, from Williamson et al. (67).

ketogenesis could contribute to a shortage of NADH; however, it does not inhibit gluconeogenesis, since the NADH that
is required for gluconeogenesis is presumably provided by
lactate dehydrogenase.
A significant amount of futile cycling is calculated to
occur through the PK-PC system during lactate perfusion,
with 60% of the carbon through PC recycled through PK
(Fig. 3). This probably overestimates the actual amount of
recycling, but there is considerable disagreement in the
literature as to the actual extent of recycling. Experiments
on livers from fasted rats, perfused with various labeled
substrates (pyruvate, alanine, propionate), yielded PK recycling values of 26 – 45% (21, 31, 42). Earlier studies using
isolated hepatocytes incubated with lactate have reported
PK recycling of ⬍10% (50). In vivo studies with [13C]lac-

tate or [13C]propionate have reported higher PK recycling
rates, 45–53% (31, 33, 35). More recently, Jin et al. (30)
used a combination of [13C]propionate and [3,4-12C]glucose
to determine an in vivo PK recycling of 70%; however, this
high PK recycling value could be attributed to the amount of
glucose infused, which could reflect a change in nutritional
state of the animal.
The addition of fatty acids to the perfusion medium stimulates gluconeogenesis from lactate, perfectly matching the
experimental data (Fig. 3). Moreover, fatty acids also increase
the activity of PC and inhibit the activity of PDC, presumably
via generation of AcCoA and NADH. The inclusion of the
regulatory terms for AcCoA in the kinetic expressions for these
two enzymes is essential for achieving the correct rate of
lactate uptake and gluconeogenesis.

Fig. 6. Gluconeogenic fluxes calculated from perfusion model using lactate as the substrate. Rats were fasted for 24 h before perfusion. Symbols are experimental
data from the literature from perfused fasted livers, using a perfusion medium of Krebs-Henseleit bicarbonate buffer with BSA, and washed human erythrocytes
in a recirculated system. Solid lines are simulations using Eqs. 1, 3, and 4, and parameters are as given in Supplemental Table S1. A: 0 ⬍ t ⱕ 30 min: saline
preperfusion (no substrate); 30 ⬍ t ⱕ 100 min: lactate (10 mM) perfusion with substrate added continuously to the medium. Œ, From Frohlich and Wieland (22);
simulations calculated with Fperfusate ⫽ 7 ml/min and Vperfusate ⫽ 100 ml. B: 0 ⬍ t ⱕ 30 min: saline preperfusion (no substrate); 30 ⬍ t ⱕ 100 min: lactate (10
mM) ⫹ FA perfusion. Œ, From Frohlich and Wieland (22); simulations calculated with Fperfusate ⫽ 9 ml/min and Vperfusate ⫽ 100 ml. C and D: 0 ⬍ t ⱕ 38 min:
saline preperfusion (no substrate); 38 ⬍ t ⱕ 100 min: lactate (10 mM). Symbols are experimental data from perfused fasted livers, with substrate added as a
single dose. Œ, From Hems et al. (27); solid lines are simulations with Fperfusate ⫽ 20 ml/min and Vperfusate ⫽ 100 ml.

In the pyruvate perfusions, the simulated glucose-to-pyruvate ratios (Fig. 5) are very similar to the average of 45%
reported from various researchers (20, 38, 51, 52, 58, 64, 65,
67), although the calculated rates of pyruvate uptake and
glucose production are generally ⬃50% lower than that observed experimentally. The rate of pyruvate uptake is determined by several factors, among them, the rate of endogenous
fatty acid oxidation (RFA-endo). In the absence of information
specific to the pyruvate perfusion, the rate RFA-endo was set to
the same values used for lactate perfusion. A simulated increase in RFA-endo increases pyruvate uptake and glucose production (data not shown), although not to the extent observed
experimentally. The simulations yield 6% conversion of pyruvate to lactate; this value compares well with the 8% reported
by Williamson et al. (64).

Pyruvate oxidation through PDC plays a major role during
the perfusion of pyruvate alone, since it provides the necessary
NADH and ATP (along with endogenous fatty acid oxidation)
required for conversion of pyruvate to glucose. Our simulation
shows that 40% of pyruvate uptake is channeled through PDC
in the absence of exogenous fatty acid (data not shown), which
is in good agreement with an average of 30% reported previously (20, 38, 51, 52, 58). The addition of fatty acids to the
perfusion medium containing 2 mM pyruvate results in an
inhibition of pyruvate oxidation to a value of 5% of pyruvate
uptake, in agreement with the 9% measured experimentally
(38). This finding demonstrates again the importance of
AcCoA, induced by the exogenous fatty acid addition, on
the control of PDC and the subsequent control of hepatic
gluconeogenesis.

Fig. 7. Gluconeogenesis from lactate and pyruvate in the livers of fasted rats. Solid lines are fluxes calculated from perfusion model using Eqs. 1, 3, and 4 with
Fperfusate ⫽ 32 ml/min. All other parameters are as given in Supplemental Table S1. Symbols are experimental data from the literature from fasted livers perfused
with Krebs-Henseleit bicarbonate buffer saturated with a mixture of oxygen and carbon dioxide. A: liver was preperfused for 10 min, followed by lactate infusion
for 24 min, followed by perfusion with buffer (no substrate) for another 20 min. Œ, From Bracht et al. (9) using a nonrecirculated retrograde perfusion; ■, from
Martins et al. (36) using a nonrecirculated anterograde perfusion. B: liver was preperfused for 10 min, followed by pyruvate infusion for 14 min, followed by
perfusion with buffer (no substrate) for another 20 min. Œ, from Bracht et al. (9) using nonrecirculating, retrograde perfusion.

Our model also allows the prediction of dynamic and steadystate responses of the liver to various substrates. As shown in
Fig. 7, the predicted transient responses to both lactate and
pyruvate infusions are very similar to that observed experimentally by Bracht et al. (9), although in the former case, the model
underestimated the steady-state glucose production by ⬃45%.
It is unclear why the results from Martins et al. (36) exhibit
significantly slower dynamics than that of Bracht et al. (9). The
calculated response to pyruvate perfusion (Fig. 5B) is characterized by a rapid (1 min) response in pyruvate uptake and
glucose and lactate production. However, after 5 min, the rate
of lactate formation begins to decrease, accompanied by a
slight reduction of the rate of pyruvate uptake and a gradual
increase in glucose production over 30 min. Very similar
dynamics have been observed in the experimental data of
Williamson et al. (64), also shown in Fig. 5B. This transient
behavior results from the balance between a very fast transport
rate (of both pyruvate and lactate), a fast lactate dehydrogenase
reaction, and relatively slower PC kinetics (data not shown),
which causes some of the initial pyruvate influx to drain out as
lactate before the gluconeogenic rate has a chance to increase.
The effects of glucagon and insulin were considered in the
model indirectly, via cAMP, which is one of the main mediators of hormonal action in the liver. The concentration of
cAMP appears directly in the kinetic expressions for FBPase
and indirectly through the allosteric constant Lp for PK (Supplemental Table S1). Moreover, cAMP affects the concentration of F-2,6-P2, which is included in PFK and FBPase kinetics
(Supplemental Table S1). Our study was limited to the fasted
state; therefore, the concentrations of cAMP and F-2,6-P2, and
the allosteric constant Lp, were fixed at values obtained from
fasted rats.
Because of the large number of reactions involved in liver
metabolism, many of the reactions in series were lumped
together. For example, the reactions of PC, malate dehydrogenase, and phosphoenolpyruvate carboxykinase (PEPCK) were
lumped together into the reaction labeled RPYR3 PEP, with
representation by the kinetics of PC. The kinetics of PC was
selected since this enzyme is allosterically regulated by
AcCoA, which is critical for correctly describing the interaction between fatty acid uptake and gluconeogenesis. On the
other hand, PEPCK is important since it can influence the
GTP-to-GDP ratio, which is critical for TCA cycle flux. However, there are no known allosteric regulators of PEPCK, and,
despite the rapid change in PEPCK mRNA, the activity of the
enzyme is slow to change in response to diet or hormones (the
enzyme has a half-life of 6 h). Furthermore, control analysis
has demonstrated that the major regulation of hepatic gluconeogenesis is distributed among several steps, including PC,
inhibition of PK, F-1-6-P2, and steps outside the classic gluconeogenic pathway.
In conclusion, the model presented in this paper is a promising tool to study the relationship between gluconeogenesis
and lipid metabolism and their role in various metabolic
disorders. The model predicts with reasonable accuracy the
effect of lipids on many of the metabolic fluxes in the liver.
After modifying the kinetic expressions used for the TCA cycle
and ketogenesis and extending the model to include gluconeogenesis and urea formation from amino acids, such as alanine,
it should serve as an in silico representation of an important
component of hepatic metabolism.
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